Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy.
Bone sarcomas
Chondrosarcoma
Ewing sarcoma
Liquid biopsy
Osteosarcoma
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
12
2020
revised:
18
03
2021
accepted:
31
03
2021
pubmed:
25
4
2021
medline:
16
6
2021
entrez:
24
4
2021
Statut:
ppublish
Résumé
Bone sarcomas, although rare, are associated with significant morbidity and mortality. The most frequent primary bone cancers include osteosarcoma, chondrosarcoma and Ewing sarcoma. The treatment approaches are heterogeneous and mainly chosen based on precise tumour staging. Unfortunately, clinical outcome has not changed significantly in over 30 years and tumour grade is still the best prognosticator of metastatic disease and survival. An option to improve this scenario is to identify molecular biomarkers in the early stage of the disease, or even before the disease onset. Blood-based liquid biopsies are a promising, non-invasive way to achieve this goal and there are an increasing number of studies which investigate their potential application in bone cancer diagnosis, prognosis and personalised therapy. This review summarises the interplay between clinical and molecular aspects of the three main bone sarcomas, alongside biomarker discovery and promising applications of liquid biopsy in each tumour context.
Identifiants
pubmed: 33894338
pii: S1040-8428(21)00128-1
doi: 10.1016/j.critrevonc.2021.103340
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103340Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.